Wells, Alvin F.
Greenwald, Maria
Bradley, John D.
Alam, Jahangir
Arora, Vipin
Kartman, Cynthia E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
THU0078 Concomitant use of conventional synthetic dmards and response to baricitinib
https://doi.org/10.1136/annrheumdis-2017-eular.1342
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis
https://doi.org/10.1007/s40744-018-0110-x
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
https://doi.org/10.1136/annrheumdis-2017-211259
AB0287 BENEFITS OF PAIN RELIEF ON FATIGUE, FUNCTION, AND QUALITY OF LIFE WHEN JOINT INFLAMMATION IS CONTROLLED IN PATIENTS WITH RA
https://doi.org/10.1136/annrheumdis-2019-eular.542
AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-eular.1995
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-214529
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
POS0646 RAPID AND CONCURRENT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS WITH BARICITINIB IN RA-BEAM
https://doi.org/10.1136/annrheumdis-2021-eular.65
POS0649 BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.182
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
https://doi.org/10.1136/rmdopen-2017-000581
P092 Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis from a phase 3 study
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.108
THU0114 Effects of smoking on baricitinib efficacy in patients with rheumatoid arthritis: pooled analysis from two phase 3 clinical trials
https://doi.org/10.1136/annrheumdis-2017-eular.1341
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
FRI0048 NUMBER NEEDED TO TREAT TO ACHIEVE MINIMUM CLINICALLY SIGNIFICANT DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN PATIENTS TREATED WITH BARICITINIB
https://doi.org/10.1136/annrheumdis-2020-eular.1440
SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1346
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Robust analyses for radiographic progression in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2022-002543
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2017-000546
Funding for this research was provided by:
Eli Lilly and Company
Incyte Corporation
Article History
Received: 9 February 2018
First Online: 21 April 2018